Improving Prostate Cancer Diagnosis & Prognosis One Patient at a Time.
- Multicolor labeling of prostate cancer tissue using the Proveri protocol that eliminates autofluorescence in paraffin embedded tissue. Tumor (green, Alexa 488) was labeled with anti-AMACR while stroma, red (Alexa 594), was labeled with anti-ACTA2, a Proveri-identified stroma-specific biomarker. All nuclei, blue, are labeled with DAPI. Even at cellular resolution (0.32 microns/pixel), the background is undetectable (black) (digital micrograph taken at 20x magnification)... Read more
-
Prostate cancer suppresses expression of PDLIM7. Stroma cells within infiltrating tumor (upper inset) label with anti-COL4A2 (red, Alexa 594) but not with anti-PDLIM7 while stroma remote from tumor (lower inset) readily exhibit both COL4A2 (red, Alexa 594) and PDLIM7 (green, Alexa 488). All nuclei, blue, are labeled with DAPI. (digital micrograph taken at 20x magnification)... Read more
- Illustration of Proveri Inc. biomarkers specific to stroma elements of prostate cancer tissue. Anti-SVIL (green (Alexa 488), specifically labels fibroblasts and myofibroblasts while anti-COL4A2 (red (ALEXA 594), is expected to label basement membranes and in prostate cancer tissue binds to stroma vascular elements. (digital micrograph taken at 20x magnification.)... Read more
At Proveri Inc. we develop innovative diagnostic and prognostic tests for prostate cancer, providing both patients and physicians with critical information for informed treatment choices.
News & Events
Diagnosis of Prostate Cancer Using Differentially Expressed Genes in Stroma published in AACR Journal
Our Products
Learn about our prostate cancer screening solution PPCA™ and future product development cycle.
Prostate Cancer
Learn more about prostate cancer and current diagnostic tests to screen for its presence.
Information Requests
Learn more about investment opportunities, partnerships and how to contact Proveri team members.
